Print this page    •   Back to Web version of article

U.S. News
Ranbaxy, GlaxoSmithKline Settle Dispute Over U.S. Patent Covering Valtrex

July 26, 2007

Under an agreement announced today, Indian pharmaceutical company Ranbaxy Laboratories Inc. will be allowed to introduce generic copies of the herpes drug Valtrex in the United States in the latter half of 2009. Ranbaxy will have 180 days of exclusivity to sell the pill here. The arrangement between Ranbaxy and GlaxoSmithKline PLC clears the way for the British drug company to drop the suit it filed in 2003 in a US court to stop Ranbaxy from selling generic copies of Valtrex. GSK's patent on Valtrex is due to expire in the United States and most European countries in 2009. In February, the US Food and Drug Administration approved Ranbaxy's plan to make and market generic Valtrex.

Back to other news for July 2007

Excerpted from:
Associated Press
07.26.2007




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art42478.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.